24/7 Market News Snapshot 14 April, 2025 – Verve Therapeutics, Inc. Common Stock (NASDAQ:VERV)

April 14, 2025

DENVER, Colo., 14 April, 2025 (www.247marketnews.com) – (NASDAQ:VERV) are discussed in this article.
Verve Therapeutics, Inc. (VERV) is gaining substantial market attention, driven by the promising early results from its Heart-2 Phase 1b clinical trial of VERVE-102, a novel gene-editing therapy targeting cardiovascular disease. In pre-market trading, VERV has surged to $4.68, marking a substantial 43.56% rise from the prior closing price of $3.26, with a trading volume of 1.85 million shares indicating heightened investor interest and potential for sustained growth.

VERVE-102 focuses on addressing critical patient populations, notably individuals with heterozygous familial hypercholesterolemia (HeFH) and those suffering from premature coronary artery disease (CAD). This investigational therapy offers the promise of significant reductions in low-density lipoprotein cholesterol (LDL-C), which is vital for effective cardiovascular disease management. Preliminary data from a study involving 14 participants highlighted a favorable safety profile, showing no treatment-related serious adverse events. The therapy produced impressive dose-dependent reductions in both blood PCSK9 protein levels and LDL-C, with mean reductions of 53% and a maximum reduction of 69% observed in the highest dose cohort.

Dr. Eugene Braunwald, a prominent figure in cardiovascular research, underscores the significance of these findings, emphasizing the urgent need for innovative therapeutics. He indicates that traditional therapies often see high rates of discontinuation within the first year, failing to maintain adequate LDL-C management. Verve’s advanced GalNAc-LNP delivery technology uniquely targets the PCSK9 gene in liver cells, suggesting the potential for a more enduring treatment solution that could redefine patient care in cardiovascular health.

Looking ahead, Verve Therapeutics plans to announce final data from the Heart-2 trial in the latter half of 2025 and will initiate a Phase 2 clinical trial shortly thereafter. With substantial financial resources projected to support operations through mid-2027, the company is strategically positioned to make significant contributions to the field of cardiovascular medicine.

Related news for (VERV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.